Full Press Release Details
Alterity qualifies for temporary relief
from NASDAQ regarding
Minimum Bid Price Requirement
MELBOURNE, AUSTRALIA AND SAN FRANCISCO,
USA - 22 April 2020: Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from NASDAQ advising
that as a result of NASDAQ COVID-19 relief, it qualifies for temporary relief from compliance with the $US1.00 minimum bid price
Alterity previously advised it had received
notification from NASDAQ of a minimum bid price deficiency as a result of having a closing bid price per ADS below $US1.00 for
30 consecutive trading days. This temporary relief extends the time for Alterity to regain compliance from August 3, 2020 to October
If at any time until October 19, 2020 the
closing bid price per ADS is at least $US1.00 for at least ten consecutive business days, NASDAQ will provide the Company written
confirmation of compliance and the matter will be closed.
As previously advised, the NASDAQ notification
has no effect at this time on the listing of the Company's American Depositary Shares ("ADSs") and the ADSs will continue
to trade uninterrupted on NASDAQ under the symbol "ATHE". The Company's ordinary shares which are traded on the
Australian Securities Exchange ("ASX") under the symbol "ATH" are in full compliance with ASX listing requirements
and are completely independent of the NASDAQ listing.
Authorisation & Additional information
This announcement was authorised by Geoffrey Kempler, CEO and Chairman of Alterity Therapeutics Limited.
Rebecca Wilson, WE Communications
About Alterity Therapeutics
Alterity's lead candidate,
PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated
in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of -synuclein and tau proteins in animal models
of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical
Parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
For further information please
visit the Company's web site at www.alteritytherapeutics.com.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities
Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects,"
"intends," "hopes," "anticipates," "believes," "could," "may," "evidences"
and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that
could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections
titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form
20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development
program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development
program, including, but not limited to, PBT434, and any other statements that are not historical facts. Such statements involve
risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in
financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including,
but not limited to, PBT434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the company's
business, operations and employees, the ability of the Company to procure additional future sources of financing, unexpected adverse
side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT434, that could
slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade
secrets, including, but not limited to, the intellectual property relating to PBT434.
forward-looking statement made by us in this press release is based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to publicly updated any forward-looking statement, whether written
or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.